---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042975"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2026-09-16T22:05:39+00:00"
generated_at: "2026-09-17T10:06:11.564002+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Impact Biomedical: Zoar files Form F-4 for merger; closing still subject to SEC, shareholder vote, listing

## Summary
- Zoar Limited filed Form F-4 with SEC on Sept 10, 2026 for proposed merger with Impact Biomedical (NYSE: IBO).
- Combined company to focus on active pharmaceutical ingredients and intermediates for therapeutic areas.
- Completion requires SEC effectiveness, Impact stockholder approval, and NYSE American listing of PubCo ordinary shares.
- Preliminary proxy statement/prospectus included; definitive version to be mailed after effectiveness.

## SEC filing metadata
- accession: 0001493152-26-042975
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2026-09-16T22:05:39+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315226042975/0001493152-26-042975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315226042975/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042975
- JSON: https://secwatch.observer/filing/0001493152-26-042975.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.